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Abstract
Background—The evaluation of sputum leukocytes by flow cytometry is an opportunity to
assess characteristics of cells residing in the central airways, yet it is hampered by certain inherent
properties of sputum including mucus and large amounts of contaminating cells and debris.
Objective—To develop a gating strategy based on specific antibody panels in combination with
light scatter properties for flow cytometric evaluation of sputum cells.
Methods—Healthy and mild asthmatic volunteers underwent sputum induction. Manually
selected mucus “plug” material was treated with dithiothrietol, filtered and total leukocytes
acquired. Multicolor flow cytometry was performed using specific gating strategies based on light
scatter properties, differential expression of CD45 and cell lineage markers to discriminate
leukocytes from squamous epithelial cells and debris.
Results—The combination of forward scatter and CD45 expression reliably segregated sputum
leukocytes from contaminating squamous epithelial cells and debris. Overlap of major leukocyte
populations (neutrophils, macrophages/monocytes) required the use of specific antibodies (e.g.
CD16, CD64, CD14, HLA-DR) that differentiated granulocytes from monocytes and
macrophages. These gating strategies allowed identification of small populations of eosinophils,
CD11c+ myeloid dendritic cells, B cells and NK cells.
Conclusions—Multicolor flow cytometry can be successfully applied to sputum samples to
identify and characterize leukocyte populations residing on the surfaces of the central airways.
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INTRODUCTION
Flow cytometry (FCM) is a useful tool for a variety of both clinical diagnostic and research
applications and is used extensively for immunophenotyping blood. The rationale for its
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application to sputum is based on the fact that induced sputum techniques provide a
mechanism for procuring viable cells derived from surfaces of central airways (Alexis et al.
2001b), a region of the lung which is difficult to sample non-invasively in humans. While
sputum induction retrieves sufficient cells for FCM, its application to sputum samples
remains relatively novel, despite its potential for yielding valuable information on the
functional and phenotypic characteristics of inflammatory and immune cells residing on
bronchial surfaces.
Unlike blood and bronchoalveolar lavage (BAL) samples, sputum contains variable amounts
of mucus, contaminating epithelial cells and endogenous or exogenous debris which can
render FCM analysis challenging, likely causing reluctance by many investigators to use it
for evaluating sputum. As a result, BAL cells are often used as surrogates for cells residing
in the central airways; however, this is less than optimal because these techniques sample
different regions of the lung (central airways vs. alveolar parenchyma) and the leukocyte
composition (Table 1) is quite different between the two. (Balbi et al. 2007; Bienkowska-
Haba et al. 2002; Pizzichini et al. 1998; Grootendorst et al. 1997; Alexis et al. 2000) BAL
and sputum cells also possess different functional and phenotypic characteristics. (Alexis et
al. 2000) For these reasons, application of FCM to sputum samples (as opposed to BAL) is,
in our view, preferable and, perhaps, more appropriate for assessing inflammation of the
bronchial airways.
Early studies, (Alexis et al. 2001a; Alexis et al. 2000) as well as some more recent FCM
studies from other labs were somewhat technically limited in that they relied primarily on
light scatter properties for gating sputum populations and used only two fluorochromes
(FITC and PE) for analysis of sputum. Thus anti-CD45, a critical marker for differentiating
leukocytes from debris was generally not used. As a result, the purity of gated leukocyte
populations in these studies likely suffered. Some studies have used specific cell lineage
markers (e.g.: CD3, CD4, CD14, HLA-DR or other markers) to identify and gate specific
cells of interest (Barry et al. 2002; Barry and Janossy2004; Frankenberger et al. 2004;
Janossy et al. 2008; Holden et al. 2008; McCarthy et al. 2007) and a few more recent studies
(Leckie et al. 2003; Dominguez et al. 2004; Jaksztat et al. 2004; Lay et al. 2007; Alexis et al.
2009; Antoniou et al. 2005; Dua et al. 2010) employed more intricate approaches; however,
none have provided detailed descriptions of a comprehensive and rigorous approach using
FCM for differentiating sputum leukocytes from debris.
Here we describe strategies using a combination of light scatter properties, CD45
expression, and differential expression of lineage-specific cell surface markers which allow
more confident identification of sputum leukocytes. Antibody combinations were designed
to assess expression of specific cell surface proteins associated with innate and adaptive
immunity. Surface proteins associated with innate immune function include Fc-gamma
receptors (FcγRI/CD64 and FcγRIII/CD16), the LPS receptor (CD14) and complement
receptors (CR3/CD11b; CR4/CD11c), as well as Toll-like-receptors 2 and 4 (CD282 and
CD284, respectively) and the low- and high-affinity IgE receptors (CD23/FcεR-IIα and
FcεRIα, respectively). These are found primarily on mononuclear phagocytes and
granulocytes and to lesser degree on other leukocytes. While they function primarily in the
innate immune system, their functions also overlap with adaptive immune responses.
Proteins associated primarily with adaptive immune responses include HLA-DR/MHC-II,
co-stimulatory molecules CD80/B7.1, CD86/B7.2, CD40 and CD83 (tubes 4, 5 and 6),
which are expressed primarily on antigen presenting cells (APC) including DCs, monocytes,
macrophages and lymphocytes. They function in antigen presentation and activation of T-
cells and B-cells to elicit antigen specific immune responses and modulate immune-
mediated inflammation.
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The methods described here provide detailed guidance to investigators in both research and
clinical settings who wish to use FCM for evaluating sputum samples.
METHODS
Extended descriptions and discussion of methods presented here are included in the
Appendix.
Subjects and IRB approval
Induced sputum was obtained from both healthy and mild allergic asthmatic or allergic non-
asthmatic volunteers under our screening protocol which was reviewed and approved by the
University of North Carolina Committee on the Rights of Human Subjects (Institutional
Review Board). Asthmatic volunteers had mild symptoms of asthma as defined under
section 3 of the 2007 NHLBI guidelines for the diagnosis and management of asthma and all
had a positive methacholine challenge test (PC20 ≤ 10 mg/ml), defined as a 20% decrease
from the baseline forced expiratory volume in the first second (FEV1) following an inhaled
provocative challenge dose of ≤ 10mg methacholine/ml. Atopy was demonstrated by a
positive immediate skin test response to one of the following allergen mixes: 2 species of
house dust mite (Dermatophagoides farinaea and Dermatophagoides pteronyssinus),
cockroach, tree mix, grassmix, weedmix, moldmix1, moldmix2, rat, mouse, guinea pig,
rabbit, cat or dog.
Sample Collection and Processing
Sputum induction and processing techniques are based on the those of Hargreave et al
(Hargreave et al. 1998) and are detailed elsewhere. (Alexis et al. 2000) Briefly, only the cell-
enriched mucus “plugs” manually selected from the surrounding clear fluid were processed
to minimize squamous cell contamination and dilution from saliva. (Pizzichini et al. 1996;
Spanevello et al. 1998; Alexis et al. 2006) Sputum samples should immediately be placed on
ice and processed within 2 hours.(Efthimiadis et al. 2002a) Excessive or prolonged exposure
to dithiothrietol (DTT) during processing adversely affects both cell viability and surface
marker expression (Efthimiadis et al. 1997; Loppow et al. 2000) and should be avoided. (See
the appendix for additional discussion).
Antibody Panels and Staining Procedures
“Standard” antibody panels (Table 2) were used for identifying leukocyte populations and
assessing expression of select cell surface proteins associated with innate and adaptive
immunity, antigen presentation and inflammation. Anti-CD45 (leukocyte common antigen)
was included in all sample tubes to help differentiate leukocytes from debris and assist in
identifying leukocyte populations. Major lineage markers such as CD16, CD14, HLA-DR,
CD3, CD19 and CD56 were used to aid in isolating specific populations. Certain antibodies
were included in multiple sample tubes to facilitate gating of specific populations.
Incorporation of additional fluorochromes would be advantageous, allowing consolidation
of tubes and conservation of cells. Though we have done this in some panels for specific
protocols, it is often difficult to procure specific antibodies labeled with the desired
fluorochrome.
Specific staining procedures have been described elsewhere (Alexis et al. 2000) and in the
Appendix. Following staining, cells were fixed in 1% paraformaldehyde in Dulbecco’s
phosphate-buffered saline (DPPS) and FCM performed within 24 hours. Stained samples
should be refrigerated at 4°C until acquired. Sources for specific antibodies are listed in the
appendix (Table 4). Specific antibodies were titrated to determine an appropriate amount for
staining. We found it necessary to titrate and dilute isotype controls up to 1:5 (or more),
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especially for IgG2 isotypes since non-specific binding resulted in fluorescent intensity of
the isotype control exceeding that of certain specific antibodies. Though fluorescence minus
one (FMO) (Tung et al. 2004) controls would be preferable to isotype controls for
determining background fluorescence, it was not feasible since it would require an excessive
amount of cells to be performed properly. (See the appendix for additional discussion of
isotype controls.)
Determination of Background Fluorescence Using Isotype Controls
Mean fluorescence intensity (MFI) of isotype controls (Tubes 1 and 2, Table 2) for specific
populations was subtracted from the MFI measured for specific markers to control for
background auto-fluorescence and non-specific fluorescence. For individual populations,
background fluorescence was determined simultaneously for all fluorescence channels by
creating a single histogram and gating 99% of the population (95% at the minimum) in only
one fluorochrome channel, usually FITC. As illustrated for the monocyte population (Table
3), background MFIs for the various fluorochromes were relatively constant regardless of
which channel was used for gating. This is also true for the other leukocyte populations and
avoids the creation of a very large number of histogram gates.
Instrument Setup
We used a BD™ LSR-II digital flow cytometer equipped with 405nm solid state, 488nm
argon-ion, and 633nm Helium-Neon lasers, appropriate filters and capability for cross-laser
compensation (BD Biosciences Immunocytometry Systems, San Jose, CA). Our “standard”
panel uses 5 colors exciting off the 488 and 633 lasers; however, additional fluorochromes,
including those exciting off the 405 laser, are used in some studies. Compensations for
spillover and spectral overlap were established for a particular set of instrument settings
using BD™ CompBeads (BD Biosciences, cat 552843) and an automated compensation
algorithm in BD™ FACSDiva 6.1 software (BD Biosciences).
The high auto-fluorescence of sputum macrophages, relative to lymphocytes, requires a
compromise to allow application of a single set of PMT voltages for all populations. Our
approach has been to optimize instrument settings for monocytes. (see Appendix)
STATISTICS
Statistical evaluation was performed using GraphPad Prism 5.03 software. Non-parametric
statistics (Wilcoxon Signed Rank test or Mann-Whitney test) were used to compare groups.
Spearman’s correlation was used to test correlation. Least-squares goodness of fit was used
to calculate linear regression.
RESULTS
Identification of leukocytes in sputum samples
Figures 1 through 5 represent typical moderately contaminated sputum samples from healthy
and mild asthmatic volunteer subjects and demonstrate a typical level of contaminating
debris, moderate to high proportion of squamous epithelial cells and small proportion of
EOS.
The levels of contamination in dot plots of a relatively uncontaminated and a more typical
moderately “dirty” (i.e. contaminated) sputum sample are demonstrated in Figure 1A and B,
respectively. Due to the broad range of cell size and granularity, forward and side scatter
(FSC and SSC, respectively) was best displayed using a log scale.
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In the majority of samples, leukocytes could not be reliably identified using light scatter
properties alone, because they are intermingled with contaminating epithelial cells, detritus
from dead cells, yeast, bacteria, micro-particles and exogenous inhaled particles. It was
therefore essential to include anti-CD45 (leukocyte common antigen) in the antibody
cocktail to facilitate leukocyte identification. Even though “leukocytes,” expressing CD45
could be segregated from the whole sample (Fig 1C), it is clear that, based on FSC (Fig 1D),
a large proportion of the CD45(+) material is much smaller (lower FSC) than expected for
leukocytes. We postulated that this is likely due to specific or non-specific CD45 staining of
fragmented cell membranes and cell detritus, or diffusion of labeled antibody through leaky
membranes of apoptotic, pyknotic or degenerate cells. This is supported by the fact that the
majority of this CD45(+)/FSClow material stains positive with propidium iodide (PI), a cell-
impermeant stain for viability, as demonstrated in Fig1E. To address this artifact, it was
essential to exclude this material based on FSC (Fig1F, High FSC gate), especially for very
“dirty” samples. All subsequent gating was done using the “cleaned” CD45 (+) cells (Fig
1F).
Leukocyte populations are similarly positioned in both blood and sputum, based both on
light scatter properties and CD45 expression. Neutrophils (polymorphonuclear cells, PMNs)
are usually abundant in sputum samples even in healthy individuals and, as in blood,
lymphocytes are the smallest and least granular cells in sputum. PMN and, when present,
lymphocyte populations served as convenient “landmarks” for locating sputum leukocytes
by FCM. The use of density plots (as opposed to dot plots) can facilitate identification of
PMN in sputum samples Fig 1C – H). The simplest gating strategy for leukocyte sub-
populations was based on SSC and differential CD45 expression (Fig 1G). However, as
demonstrated in the following sections, more complex strategies were required to adequately
discriminate overlapping populations and subpopulations, especially small or rare-event
populations (e.g. EOS, DCs, and basophils) and detection of dimly expressed surface
proteins.
When present in sufficient number, squamous epithelial cells appeared as a separate
population with high forward and side scatter (Fig 1B & C) and might easily be mistaken for
macrophages. However, in contrast to macrophages, this population does not express CD206
(macrophage mannose receptor, Fig 1H) or HLA-DR (not shown) and was absent from
samples having minimal squamous cells based on examination of stained slides (not shown).
Specific Gating Strategies
We have found that analysis was facilitated if lymphocyte and granulocyte populations were
identified and gated first. Lymphocytes could be identified based on SSC and CD45
expression alone (Fig 2A). Granulocytes were identified within the non-lymphocyte gate
(P2) using specific markers (e.g., CD64, CD16, CD14 or HLA-DR) which allowed for their
discrimination either through positive or negative selection. Remaining non-granulocytes
comprised monocyte, macrophage and DC populations, which were further differentiated
based on differential SSC properties, CD45 expression and specific surface markers.
Depending upon the antibody panel, it was not always possible to differentiate small
populations such as DCs or EOS; however, inclusion of additional population-specific
antibodies could facilitate their identification (see below).
Though differential expression of so called “lineage-specific” markers greatly facilitates
discrimination of leukocyte populations, some overlap in expression of these molecules on
various populations does occur (e.g. CD23 and CD14 on activated PMNs) and may result in
less than optimal separation. As a result, gating necessarily becomes relatively more
subjective and may vary depending upon the bias of individual analysts. Though this is
largely unavoidable, subjectivity and misidentification of populations can be minimized by
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gating strategies based on two differentially-expressed markers or sequential “Boolean”
gating strategies using two or more markers. The use of relatively conservative gating (i.e.
gating tightly around populations) in such situations will also help to minimize
misidentification of populations.
Evaluation of Innate Immune Response Proteins (Table 2, Tubes 3, 7 & 8)
Lymphocytes could be gated confidently based on SSC and CD45 expression (Fig 2A):
however, antibodies against specific cell surface proteins were utilized to differentiate
overlapping populations of PMNs, EOS and mononuclear phagocytes. Differential
expression of CD64 and CD16 (tube 3) permitted isolation of PMNs, EOS and DCs from
remaining monocytes and macrophages (Fig 2B). Neutrophils and EOS were differentiated
based on CD16 expression (Fig 2 C). Keep in mind that degranulated EOS will have lower
SSC properties and may blend with the PMNs based on SSC. The remaining non-
granulocytes (Fig 2C) were monocytes, macrophages and DCs, which were recombined with
the “not-P3”population (Fig 2B) and further partitioned on the basis of light scatter and
differential expression of CD45, CD16 and CD14 (Fig 2D & E). Dendritic cells (Fig 2E)
were identified as CD14dim/CD16dim and fell primarily within the monocyte population.
Granulocytes in tube 7 (Fig 2F) were identified as HLA-DRdimCD14dim/neg cells and DCs
could be identified as CD14dim//HLA-DRhigh non-lymphocytic cells (Fig 2G). The
proportions of DCs identified in tubes 3 and 7correlated well with the more definitive
identification of DCs and their identity can be verified using the lineage cocktail (not
shown) as in tubes 4 and 5 (described below).
The expression of CD14 on activated PMNs (tube 8) often prevented good separation of
PMNs from mononuclear phagocytes based solely upon CD14 expression. Differential
expression of CD14 in combination with either CD23 or FcεRIα (dim expression on
granulocytes) was used to facilitate isolation of granulocytes in this tube (Fig 2H). Though
some activated PMNs and EOS may express low to moderate levels of these surface
proteins, they are expressed at relatively low levels compared to mononuclear phagocytes.
Inclusion of anti-HLA-DR would allow better discrimination of mononuclear phagocytes
and identification of DCs.
Evaluation of Adaptive Immune Response Proteins (Table 2, Tubes 4, 5 and 6)
Dendritic cells were specifically identified (tubes 4 and 5) within the entire CD45(+)
leukocyte population as Lineagedim/negative/HLA-DRhigh cells (Fig 3A). The lineage cocktail
(Table 2) allowed differentiation of DCs from monocytes, macrophages, granulocytes, T-
cells, B-cells and NK cells. Similar to blood, sputum DCs comprised a very small proportion
(0.5 – 1.5%) of total sputum leukocytes and were dispersed mainly within the monocyte
population (Fig 3B). The majority (≈ 90 to 95%) of sputum DCs were CD11c (+) myeloid
DCs (Fig 3C), expressing high levels of CD86. Around 50% or more constitutively
expressed CD83 while only a small proportion expressed CD1a (Fig 3D), suggesting that
airway luminal DCs are relatively mature and at least partially activated. Subsets of DCs
(Fig 3E) expressed both TLR2 and TLR4 (tube 7).
Granulocytes were differentiated within the remaining (non-DC) cells based on a
combination of SSC properties, differential expression of lineage markers and the negative
or dim expression of either HLA-DR or co-stimulatory molecule CD86 (Fig 3F) in tube 4 or
CD83 in tube 5. EOS were differentiated from PMNs as lineage-dim granulocytes (Fig 3F),
similar to Fig 2C. Though granulocytes can usually be differentiated from mononuclear
phagocytes on the basis of HLA-DR alone (Fig 3G), the use of a combination of two
differentially expressed markers is preferable when possible. In most cases, the separation of
granulocytes was well-defined; however, some PMNs and EOS may express low levels of
Lay et al. Page 6













HLA-DR and/or co-stimulatory molecules (CD80 and CD86), sometimes making the
distinction between the populations less discrete. Mononuclear phagocytes were further
dissected via SSC and differential expression of CD45 (see Fig 2D).
Differential expression of CD206 and HLA-DR (tube 6) allowed discrimination of
granulocytes from macrophages (see Fig 1H). We found that CD80 was occasionally
expressed at moderate levels on a small proportion of sputum granulocytes (Fig 3H).
Though HLA-DR (+) lymphocytes are, for the most part, CD40 (+) B-cells (see Fig 4D) and
also express some level of CD86, some activated T-cells may also express these proteins.
Inclusion of additional antibodies to specifically identify B cells (tubes 4 and 5) and either
lineage cocktail or CD14 to allow identification of DCs (tube 6) would be advantageous.
Sputum Lymphocytes
Lymphocytes (tubes 9 and 10, Table 2) comprise a small and quite variable proportion of
sputum leukocytes which is influenced by various factors including the health status of the
individual and inflammatory processes in the bronchial airways. In this cohort of
healthy,mild asthmatic and atopic individuals, the majority (≈ 80 to 90%) of sputum
lymphocytes were CD3 (+) T cells, predominantly (≈ 60 to 65%) CD4 (+) T-helper cells
(Fig 4A). B cells and natural killer (NK) cells comprised small and highly variable
proportions (Fig 4B) of the lymphocytes. The majority of CD16/56 (+) NK cells were CD3
(+) NKT cells (Fig 4C). B cells (tube 6) were identified as HLA-DRhigh/CD40 high
lymphocytes (Fig 4D). In the absence of CD56, NK cells could be tentatively identified as
CD14dim/CD11bhigh/CD16high cells (tube 3) within the lymphocyte population (Fig 4E).
Gating for Isotype Controls
Measurement of background auto-fluorescence and non-specific staining was accomplished
using isotype controls (Tubes 1 & 2 – Table 2). Lymphocytes could be gated easily since
they do not overlap significantly with other populations. Simple gating of major populations
based on SSC and CD45 expression may be adequate (see Fig 1G) for isotype controls;
however, gating based on auto-fluorescence (FITC channel) and SSC (Fig 5A) usually
provided better discrimination of overlapping granulocyte and macrophage populations.
EOS overlap with both PMN and macrophage populations, while DCs are dispersed within
the monocyte population. If present in sufficient numbers, the EOS gate could be based on
the segregated granulocyte population (Fig 5B). After isolating granulocytes, the remaining
monocytes and macrophages could be gated based on differential CD45 and SSC (Fig 5C)
Regardless of which approach was used (FITC autofluorescence or CD45 vs. SSC), small
populations such as EOS, DCs and basophils (extremely rare) were difficult (or impossible)
to isolate without specific antibodies. Figure 5D shows the locations of the EOS and DC
populations as determined by specific gating methods using tube 4 (see Fig 3 A and F). A
simplistic alternative solution was to “non-specifically” gate the locations where these small
populations are expected to exist or to substitute background auto-fluorescence values of
their parent populations (i.e. monocytes for DCs, lymphocytes for basophils and PMNs for
EOS). This is the approach we have taken for determining background fluorescence for
DCs.
Specific Examples for Evaluating Airways Disease and Response to Inhaled Pollutants
(Ozone)
The gating strategies and antibody panels described above are useful for monitoring
expression of cell surface proteins or quantification and characterization of rare-event
populations such as dendritic cells. The usefulness of these strategies for evaluating airways
inflammation associated with asthma or exposure to environmental air pollution is
demonstrated in Figure 6. As an example, using FCM, a slight yet significant (p<0.01)
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increase in the proportion of sputum dendritic cells was demonstrated (Fig 6A) in allergic
individuals sensitive to dust mites (N=29; 19 mild allergic asthmatics and 10 allergic non-
asthmatics) compared to healthy individuals (N=44). The value of flow cytometry in
evaluating the effects of air pollutant exposure is exemplified by changes in surface
expression of CD14 and HLA-DR on sputum monocytes (Fig 6B) from healthy volunteers 4
hours following a 2-hour inhalation exposure to 0.4 ppm ozone. (Hernandez et al. 2010).
Flow Cytometry-based Differential Cell Counts of Sputum Samples
Proportions of the various sputum leukocyte populations, as estimated by FCM, were similar
but not identical to those determined by light microscopy. Differences between the two
methods are variable and are affected by multiple factors, including the level of
contamination of the sputum sample, cell viability, squamous cell count, and quality of the
stained slide. For all major populations, as demonstrated for PMNs in Figure 6, there is
generally greater correlation between methods when the sample is minimally contaminated
and slide quality is high, as assessed by quality of staining and density of cells on the slide.
Based on cell counts derived from tube 4, we found a significant correlation (p < 0.0001,
Spearman’s r = 0.8233) between % PMN determined by FCM vs. microscopy (N=45 paired
observations). The linear regression line (R2= 0.8856) and 95% confidence interval are
shown (Fig 6C) for a subset of samples (N=30, filled circles) having cell viability ≥ 70% and
squamous epithelial cell count ≤ 30% (based on differential counts from stained slides).
Remaining samples (N=15, open circles) with higher squamous cell counts and lower
viability are also plotted. When all 45 samples are included in the regression, R2 drops to
0.6658. Similar correlations were found for macrophages (not shown). Lymphocyte
proportions, as determined by FCM, tended to be higher than those determined by
microscopy (Fig 6D), as were those of EOS (not shown), both of which are present in
relatively low proportions compared to PMNs and macrophages.
DISCUSSION
Inherent difficulties and artifacts peculiar to sputum render FCM challenging and necessitate
specific gating strategies for both major and rare leukocyte populations such as DCs.
Specifically, these include the presence of mucus, squamous and bronchial epithelial cells,
dead and degenerate cells, cell detritus, microparticles and exogenous contaminants such as
bacteria, yeast, pollen and inhaled dust particles. In addition, the presence of macrophages
with inherently high auto-fluorescence necessitates a level of compromise when optimizing
instrument settings. Unlike blood, overlapping major sputum leukocyte populations are not
readily discernable and are further obscured by contaminating epithelial cells and debris
which prevents efficient resolution of leukocyte populations by light scatter properties alone.
Here we have outlined methods for overcoming these difficulties, including specific gating
strategies for differentiating leukocytes from debris and identification of leukocyte
subpopulations using a combination of light scatter properties and differential expression of
CD45 and lineage-specific cell surface proteins. In addition, we have provided an approach
for evaluating expression of cell surface proteins that are associated with both innate and
adaptive immunity.
Samples with low viability are poorly suited for FCM due to excessive contamination with
cellular debris, increased non-specific staining and increased auto-fluorescence. Our
experience suggests that seventy percent viability or higher (50% at minimum) is desirable
for FCM of sputum. Damaged cells may also generate staining artifacts in that labeled
antibody may bind, specifically or non-specifically, to fragmented cell membranes and cell
debris, or diffuse through leaky cell membranes of intact dead cells. This may allow
inclusion of material with low FSC within the CD45(+) gate, thereby producing staining
artifact (see Fig1C – F) and erroneous gating. Thus, a combination of both FSC and positive
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CD45 expression are required since, individually, neither adequately discriminate leukocytes
from contaminants. While the use of isotype control antibody (and perhaps also unlabeled
blocking antibody) may help to control for this artifact, the potential for erroneous results
remains high when cell viability is low. It might still be possible to gain reliable data from
samples with poor viability by segregating them using a viability marker such as propidium
iodide (Fig 1E), 7-aminoactinomycin D, Calcein or other dyes. (Barry et al. 2002) Some
newer products such as the “fixable” viability stains offered by Invitrogen (LIVE/DEAD®
Fixable Dead Cell Stain Kit) may allow routine staining for both viability and surface
markers followed by fixation and subsequent acquisition on the flow cytometer the next day.
Though we have not yet tried the fixable dyes, they may work well for analysis of sputum
samples.
Overlapping expression of various “lineage-specific” proteins on different cell populations
may lead to a level of subjectivity in gating populations according to an individual’s own
style or bias. Although this is unavoidable, subjectivity and bias can be minimized and
objectivity increased by including antibodies to more than one differentially expressed
marker instead of relying on a single marker. For example, in tube 3, the combination of
CD64 and CD16 provides better separation of granulocytes than does CD16, CD14 or CD64
alone. Sequential “Boolean” gating may also be helpful in this respect. Over time, we
continue to discover improvements which could be made in our antibody panels and have
offered several suggestions as to how inclusion of certain alternate or additional antibodies
in a specific tube might provide additional benefit (e.g. the addition of HLA-DR in tube 8).
We have presented one approach to gating using tube-specific antibody panels; however,
individual investigators can tailor panel configurations to suit their own research needs.
We emphasize that induction/collection and subsequent processing may significantly impact
the quality of the sputum sample and subsequent analysis by FCM. Collection and
processing of samples should be performed by well-trained and experienced personnel to
maximize cell yield and viability and to minimize squamous cell contamination. Careful
coaching of the subject/patient during expectoration can significantly reduce squamous cell
contamination. While sample filtration will remove some proportion of the squamous cells,
it cannot replace good induction technique. We have found that selectively extracting cell-
rich mucus “plugs,” as opposed to processing the entire sputum sample, recovers the vast
majority of the sputum leukocytes, reduces squamous cell contamination and saliva
(Pizzichini et al. 1996) and greatly reduces the total volume of the sample to be processed,
thereby reducing the dilution effect on fluid phase components of sputum.
Timely sample acquisition following antibody staining (ideally the same day) is desirable to
maximize sample quality and minimize gating difficulties due primarily to
paraformaldehyde-induced signal decay and increases in auto-fluorescence, both of which
may occur over a relatively short period of time (24 – 48 hours). (Stewart et al. 2007)
Although logistical issues may prevent same-day sample acquisition, we have found that
acquisition within 24 hours of antibody staining does not compromise the integrity of the
sample and subsequent data analysis.
Summary
The methods, antibody panels and gating strategies described here were developed over the
course of ten years, evolving from two-color FCM, with gating based primarily on light
scatter properties, to present day use of multi-color FCM and specific gating strategies
which enable more accurate differentiation of sputum leukocytes from debris. Our
experience has shown that care must be taken during sputum induction and processing to
maximize the quality of the sample for FCM. Specific gating strategies based on a
combination of light scatter properties, differential expression of CD45 and lineage-specific
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markers are essential for differentiating sputum leukocytes and their subpopulations from
squamous epithelial cells and contaminating debris. Due to the significant overlap of major
sputum leukocyte populations, it is necessary to include antibody against at least one cell
surface marker (preferably two) which, either through positive or negative selection, will
facilitate differentiation of granulocytes from mononuclear phagocytes. Once identified,
additional FCM-based measurements of leukocyte surface receptors (immunophenotype)
and function (phagocytosis, oxidative burst) can be performed. Formulation of antibody
panels and gating strategies based on these principles greatly enhance the usefulness of
multicolor FCM for the evaluation of sputum leukocytes.
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Appendix: Extended Methods and Comments
Sputum Sample Collection, Processing and Factors Affecting Sample
Quality
Sputum induction and processing techniques vary and are described in detail elsewhere.
(Kips et al. 1998b; Kips et al. 1998a; Ronchi et al. 2002; Efthimiadis et al. 2002b; Hargreave
et al. 1998; Pizzichini et al. 1996; Spanevello et al. 1998) Methods used here are described
in detail elsewhere (Alexis et al. 2000) and are based on the methods of Hargreave et al.
(Hargreave et al. 1998) The quality of the sputum sample has major impact on the quality of
the flow cytometric assessment and can be influenced both by the induction process and
subsequent processing of the sample. Sputum samples should immediately be placed on ice
and processed within 2 hours.(Efthimiadis et al. 2002a) Careful processing of the sample is
crucial and it is important that both sputum induction and processing be performed by well-
trained and experienced personnel to maximize cell yield and minimize squamous epithelial
cell and salivary contamination. Excessive or prolonged exposure to dithiothrietol (DTT)
during processing adversely affects both cell viability and surface marker expression
(Efthimiadis et al. 1997; Loppow et al. 2000) and should be avoided. It is important to note
that our laboratory employs the “plug selection” method where cell-enriched mucus “plugs”
are manually selected from the surrounding clear saliva fluid and the total selected material
is then processed, rather than the “whole sample” method, where the entire raw expectorated
sample is processed. The main advantage of the plug-selection method is that it minimizes
both squamous cell contamination and dilution from saliva. (Pizzichini et al. 1996;
Spanevello et al. 1998; Alexis et al. 2006)
Construction of antibody panels
When constructing antibody panels for sputum analysis, it is essential to include anti-CD45
(leukocyte common antigen, pan leukocyte marker) in all sample tubes to help differentiate
leukocytes from debris and facilitate identification of leukocyte populations. We take
advantage of major lineage markers such as CD16, CD14, HLA-DR, CD3, CD19, CD56, as
well as differential expression of other population specific markers as an aid in isolating
specific populations and subpopulations. Certain specific antibodies are included in multiple
sample tubes to aid in identifying specific populations for gating purposes. Using these
principles, we have developed “standard” panels of fluorescent antibodies (See manuscript
Table 2) for identifying leukocyte populations and assessing expression of select cell surface
proteins associated with innate and adaptive immunity, antigen presentation and
inflammation. Many of the innate immune proteins also interact with the adaptive immune
system.
Cytometers equipped with multiple lasers are capable of simultaneously using many more
than the five fluorochromes incorporated in our standard 5-color panel. It would be desirable
to incorporate more fluorochromes in order to reduce duplication of certain markers,
consolidate tubes and conserve cells. We have done this for certain of our more specific
protocols, however it is often difficult (short of labeling antibodies in-house) to procure the
desired antibody labeled with the necessary fluorochrome to accomplish this. Individual
investigators can tailor antibody panels to incorporate additional fluorochromes and to fit
their specific research objectives.
Staining Procedures
Cells should be labeled (stained) in a timely manner (as soon as possible) following sample
processing and kept at 4 °C in the dark until acquired on the flow cytometer. Data
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acquisition should be done within 24 hours for best results.(Stewart et al. 2007) The specific
antibody staining procedures have been described elsewhere.(Alexis et al. 2000) We
routinely label 100 μl of cell suspension (1 × 106 cells/ml) based on total non-squamous
nucleated cells (i.e. leukocytes and bronchial epithelial cells). Following staining, cells were
fixed in 1% paraformaldehyde in Dulbecco’s phosphate-buffered saline (DPPS). Sources for
specific antibodies used in these panels are listed in Table 4..
Specific antibodies were titrated to determine an appropriate amount for staining. The
majority of the antibodies were still on the plateau of the titration curve when used at half
the manufactures suggested amount (i.e. 10 μl vs. 20 μl). A few (e.g., CD16, CD3) required
further dilution. Individual investigators should titrate their antibodies to determine
appropriate concentrations for their specific applications. Isotype antibodies also were
titrated; however, when we attempted to match protein concentrations and fluorochrome/
protein concentrations, we found that the isotype controls had a much higher MFI signal
than did certain of the specific antibodies, particularly for the IgG2 isotypes. We therefore
found it necessary to dilute isotype control antibodies up to 1:5 (or more). The cause of this
disparity is not entirely clear. (Hulspas et al. 2009) Some labs have advocated doing away
with isotype controls for this and other reasons (Keeney et al. 1998) while others do not.
(O’Gorman and Thomas1999). It may also be useful to employ nonspecific unlabeled
blocking antibody to help minimize non-specific staining.
Alternatively, a “cleaner” method for determination of background fluorescence might be
the use of “fluorescence minus one” (FMO) analysis (Tung et al. 2004), however, to be done
properly, this requires large numbers of cells when multiple populations, multiple specific
antibodies, multiple fluorochromes and two different isotypes (IgG1 and IgG2) are used.
Since the number of leukocytes obtained from sputum samples is often limited, the FMO
approach is usually not feasible for the typical sputum sample. Substitution of blood
leukocytes for estimating background fluorescence (Dua et al. 2010) may be adequate for
sputum lymphocytes, granulocytes and monocytes; however the absence of macrophages in
blood is an obvious problem; although this might be overcome by “spiking” sputum isotype
control tubes with blood leukocytes. In our experience, however, sputum monocytes tend to
be more granular (higher SSC) with moderately higher autofluorescence (especially in the
FITC channel) than peripheral blood monocytes.
Determination of Background Fluorescence Using Isotype Controls
Gating populations in the isotype control tubes is more complex for sputum than for blood
since, unlike blood, major non-lymphocyte populations overlap and small or rare
populations are imbedded within larger populations. More precise determination of
background fluorescence for these small populations, requires inclusion of specific
antibodies [e.g. CD9 or CD16 (EOS), CD203c (basophils), or CD14 (DCs)] in addition to
CD45 in the isotype control tube.
Mean fluorescence intensity (MFI) of isotype controls (Tubes 1 and 2, Table 2) for specific
populations was subtracted from the MFI measured for specific markers to control for
background auto-fluorescence and non-specific fluorescence. For individual populations,
background fluorescence was determined simultaneously for all fluorescence channels by
creating a single histogram and gating 99% of the population (95% at the minimum) in only
one fluorochrome channel, usually FITC. As illustrated for the monocyte population (Table
3), background MFIs for the various fluorochromes were relatively constant regardless of
which channel was used for gating. This is also true for the other leukocyte populations.
This approach avoided the creation of a very large number of histogram gates.
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The majority of our samples are acquired on a BD™ LSR-II digital flow cytometer equipped
with 405nm solid state, 488nm argon-ion, and 633nm Helium-Neon lasers, appropriate
filters and capability for cross-laser compensation (BD Biosciences Immunocytometry
Systems, San Jose, CA). Compensation for spillover and spectral overlap are set for a
particular set of instrument settings using BD™ CompBeads (BD Biosciences, cat 552843)
and an automated compensation algorithm in BD™ FACSDiva 6.1 software (BD
Biosciences). Once established, compensation values are not changed unless the established
parameter settings are altered. Our “standard” panel uses 5 colors exciting off the 488 and
633 lasers; however, additional fluorochromes exciting off the 405 laser are used in some
studies. This is determined by the availability of specific antibodies in a particular
fluorochrome and the amount of sample available. While it is true that less sample is
required when more fluorochromes are employed in a particular panel, the trade-off is that
the complexity of instrument setup, compensation and data analysis also increases.
Instrument Setup, Data Acquisition and Special Considerations for Sputum
Samples
The goal in establishing appropriate instrument settings is to establish the best signal to
noise ratio which will provide a measurable signal, while minimizing the coefficient of
variation of that signal. Optimal PMT voltages for samples containing mixed populations
(e.g. blood) are usually established based on the population having the lowest auto-
fluorescence (i.e. lymphocytes) and can be accomplished using cells or beads with low-
range fluorescent intensity.(BD Application Note2000) The high auto-fluorescence of
sputum macrophages, relative to lymphocytes, requires a compromise to allow application
of a single set of PMT voltages for all populations. Our approach has been to optimize
instrument settings for monocytes. The monocyte population, labeled only with CD45, is
displayed in a separate histogram for each fluorochrome and voltages adjusted to place the
entire monocyte population between 200 and 2000, which will place macrophages much
higher on the log scale (between 5,000 and 10,000) and lymphocytes somewhat lower,
perhaps even straddling zero. In the case of BD™ FACSDiva 6.1 software, bi-exponential
plots allow the display of events with fluorescent intensity below zero. It is best, however, to
use a setup optimized for lymphocytes if they are of primary interest.
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This research describes detailed methods to overcome difficulties associated with flow
cytometry of sputum samples, which previously has been lacking in the literature. Flow
cytometry of sputum samples can provide valuable information on inflammation and
immunological response elements in the bronchial airways for both clinical diagnostic
and research applications and can be a useful tool in inhalation toxicology for assessing
health effects of inhaled environmental pollutants.
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Figure 1. General Gating Strategies for Sputum Leukocyte Identification
(A) Relatively uncontaminated sputum sample. (B) A typical “dirty” raw sputum sample
from a mild asthmatic with extensive contamination. Density plots (C – D) more clearly
demonstrate location of neutrophils. (C) CD45(+) material including low FSC debris (D)
due to non-specific staining or auto-fluorescence. (E) Viable cells were selected (P2) based
on negative PI staining. (F) The majority of low FSC material was PI(+) non-viable cells
and debris. (G) Cleaned CD45(+) cells showing general locations of cell populations. (H)
Squamous epithelial cells are differentiated from macrophages as the CD206 negative
population.
SSC = Side Scatter, FSC = Forward Scatter, Mono = monocyte,, PMN = neutrophil, Lymph
= lymphocyte
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Figure 2. Specific Gating Strategies: (Tube 3, 7, 8) Assessment of Innate Immune Markers
(A) Sputum lymphocytes are gated separately from non-lymphoctes (P2). (B) Differential
expression of CD64 and CD16 facilitates separation of granulocytes (P3) from non-
granulocytes. (C) Eosinophils are differentiated from PMNs by differential expression of
CD16 (tube3). Remaining non-granulocytes from P3 are recombined with “Not P3” to
comprise the Mono/Mac/DC population. (D) Macrophages and Mono/DCs gated base on
CD45 vs. SSC properties. (E) CD14/CD16 dim dendritic cells (tube 3) fall primarily within
the Monocyte gate (D). (F and G) Granulocytes are HLA dim/neg cells in tube 7, while DCs
are CD14 dim/HLA high cells within the monocyte gate. (H) Granulocytes are CD14 dim/
FcεR1 dim cells in tube 8.
SSC = Side Scatter, Mono = monocyte, Mac = macrophage. DC = dendritic cell, EOS =
eosinophil, PMN = neutrophil,
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Figure 3. Specific Gating Strategies: (Tube 4, 5 & 6) Assessment of Adaptive Immune Markers
(A) Dendritic cells are lineage-dim/HLA-DR high cells from CD45(+) population and are
located primarily within the monocyte gate (B). DCs are primarily CD11c(+) myeloid DCs
(C) which express high levels of CD86. (D) The majority of DCs expressed CD83 (tube 5),
while relatively few expressed CD1a. (E) Subpopulations of DCs (tube 7) expressed TLR2
and TLR4. Granulocytes gated based on differential expression of CD86 and lineage
cocktail (F) or HLA-DR vs. SSC (G). A small proportion of granulocytes may express low
levels of CD80 (tube 6) (H).
SSC = Side Scatter, DC = dendritic cell, EOS = eosinophil, PMN = neutrophil
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Figure 4. Sputum Lymphocyte Subpopulations
(A) CD3(+) T cells are comprised predominantly of CD4(+) T-helper cells. (B) NK cells
and B cells comprise small and variable proportions of the lymphocyte population. (C)
CD3(+) NK-T cells comprise the majority of sputum NK cells. (D) Sputum B cells express
high levels of CD40. (E) Identification of NK cells (tube 3)
SSC = Side Scatter, FSC = Forward Scatter, NK = natural killer, T-ctl = cytotoxic T cell
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Figure 5. Gating Strategies for Isotype Control Tubes
(A) Gating based on auto-fluorescence (FITC) vs. SSC better separates granulocytes from
macrophages than does CD45 (see 1G). (B) EOS gated in the granulocyte population based
on CD45 vs. SSC. (C) Gating of monocytes and macrophages (non-granulocytes). (D)
Locations of EOS and DCs based on tube 4. Background fluorescence of monocytes is used
as a surrogate for DCs.
SSC = Side Scatter, FSC = Forward Scatter, Mono = monocyte, Mac = macrophage. DC =
dendritic cell, EOS = eosinophil, PMN = neutrophil
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Figure 6. Examples of Data Derived via Flow Cytometry of Sputum
(A) Proportions of sputum dendritic cells was significantly higher in dust-mite sensitive
allergic individuals (N=29) compared to healthy non-allergic volunteers (N=44). (B) CD14
and HLA-DR expression was significantly higher on sputum monocytes from healthy
volunteers 4hours after a 2-hr inhalation exposure to 0.4 ppm ozone (adapted from
(Hernandez et al. 2010). (C) There was a significant (p=0.0001) correlation between
%PMNs derived by FCM vs. stained slides (N=45). Filled circles = high viability (>70%)
and low squamous cells (<35%). Open circles = low viability or high squamous cells, (D)
Lymphocyte proportions tended to be higher based on FCM vs. stained slides.
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Table 1
Comparison of Leukocyte Populations of Blood, Sputum and BALF in Healthy Individuals.*
Cell type Blood Sputum BALF
Monos/Macs 2 – 10% (monos)† 30 – 95% 75 – 95%
Dendritic cells 0.5 – 1.0% 0.5 – 1.5% 0.5 – 1.0%
Neutrophils 40 – 75% 5 – 95 % 0 – 1%
Eosinophils 1 – 6% 0 – 1% 0 – 2%
Lymphocytes 20 – 40% 0 – 3% 0 – 23%
Bronchial Epith. NA 0 – 10% 0 – 3%
Squamous Epith. NA 1 – 60% Rare
Basophils 0 – 1% Extremely Rare Extremely Rare
Mast cells 0% 0% 0%
*
Based on references (Balbi et al. 2007; Bienkowska-Haba et al. 2002; Pizzichini et al. 1998; Grootendorst et al. 1997; Alexis et al. 2000)
†
Macrophages are absent from blood. The values for sputum and BALF include monocytes and macrophages combined.
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